Clinical Trial Update: Study of ART0380 in Patients With Biologically Selected Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study of ART0380 in biologically selected solid tumors, including recurrent endometrial cancer, was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• ART0380

Snippet

Sponsor: Artios Pharma Ltd | Conditions: Advanced Solid Tumor, Recurrent Endometrial Cancer | Phase 2 | Status: TERMINATED